Evidence map›Paper›PMID 41514610›Full record

ArticleCancers2025

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data.

Ann-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, Egle Ramelyte, Omar Hasan Ali, Thomas Kündig, Daniela Mihic-Probst, Sarah Steiner, Alexander Maurer, Reinhard Dummer and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ann-Kathrin BlumenrötherDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0009-0009-6459-6572
Yongxing FangDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Tamara El SaadanyDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Egle RamelyteDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-8262-8608
Omar Hasan AliDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-5185-7520
Thomas KündigDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-3863-8766
Daniela Mihic-ProbstDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-2215-9958
Sarah SteinerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Alexander MaurerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-6964-802X
Reinhard DummerDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-2279-6906
Joanna ManganaDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Lara V MaulDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune checkpoint inhibitionmelanomamucosalNADINAneoadjuvantpathologic responseradiologic responseSWOG S1801

Identifiers

PMID41514610
PMCPMC12785055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.